HRP20230062T8 - Formulacije buprenorfina sa produženim oslobađanjem - Google Patents

Formulacije buprenorfina sa produženim oslobađanjem Download PDF

Info

Publication number
HRP20230062T8
HRP20230062T8 HRP20230062TT HRP20230062T HRP20230062T8 HR P20230062 T8 HRP20230062 T8 HR P20230062T8 HR P20230062T T HRP20230062T T HR P20230062TT HR P20230062 T HRP20230062 T HR P20230062T HR P20230062 T8 HRP20230062 T8 HR P20230062T8
Authority
HR
Croatia
Prior art keywords
extended release
buprenorphine formulations
buprenorphine
formulations
extended
Prior art date
Application number
HRP20230062TT
Other languages
English (en)
Croatian (hr)
Inventor
Tong-Ho Lin
Yung-Shun WEN
Jui-Wei LIANG
Original Assignee
Alar Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc. filed Critical Alar Pharmaceuticals Inc.
Publication of HRP20230062T1 publication Critical patent/HRP20230062T1/hr
Publication of HRP20230062T8 publication Critical patent/HRP20230062T8/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20230062TT 2016-09-13 2017-09-12 Formulacije buprenorfina sa produženim oslobađanjem HRP20230062T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394168P 2016-09-13 2016-09-13
PCT/CN2017/101327 WO2018050043A1 (en) 2016-09-13 2017-09-12 Sustained-release buprenorphine formulations background of invention
EP17850245.6A EP3512518B1 (en) 2016-09-13 2017-09-12 Sustained-release buprenorphine formulations

Publications (2)

Publication Number Publication Date
HRP20230062T1 HRP20230062T1 (hr) 2023-03-31
HRP20230062T8 true HRP20230062T8 (hr) 2023-04-14

Family

ID=61619029

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230062TT HRP20230062T8 (hr) 2016-09-13 2017-09-12 Formulacije buprenorfina sa produženim oslobađanjem

Country Status (31)

Country Link
US (1) US10744132B2 (enExample)
EP (1) EP3512518B1 (enExample)
JP (1) JP6929367B2 (enExample)
KR (1) KR102244500B1 (enExample)
CN (1) CN109789137B (enExample)
AR (1) AR110468A1 (enExample)
AU (1) AU2017325910B2 (enExample)
BR (1) BR112019004923A2 (enExample)
CA (1) CA3033046C (enExample)
CL (1) CL2019000624A1 (enExample)
CO (1) CO2019003632A2 (enExample)
DK (1) DK3512518T3 (enExample)
ES (1) ES2934721T3 (enExample)
FI (1) FI3512518T3 (enExample)
HR (1) HRP20230062T8 (enExample)
HU (1) HUE060906T2 (enExample)
LT (1) LT3512518T (enExample)
MX (1) MX374304B (enExample)
MY (1) MY196269A (enExample)
PE (1) PE20190707A1 (enExample)
PH (1) PH12019500466A1 (enExample)
PL (1) PL3512518T3 (enExample)
PT (1) PT3512518T (enExample)
RS (1) RS63894B1 (enExample)
RU (1) RU2747306C2 (enExample)
SG (1) SG11201901294QA (enExample)
SI (1) SI3512518T1 (enExample)
SM (1) SMT202300006T1 (enExample)
TW (1) TWI743193B (enExample)
WO (1) WO2018050043A1 (enExample)
ZA (1) ZA201900890B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057075C (zh) * 1997-09-10 2000-10-04 中国石油化工总公司 低碳烯烃直接水合连续生产低碳醇的方法
TWI838372B (zh) 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
TWI827777B (zh) * 2018-12-27 2024-01-01 昱展新藥生技股份有限公司 納曲酮注射型緩釋製劑
EP3936112A1 (en) * 2020-07-07 2022-01-12 Occlugel Hydrophilic degradable microspheres for delivering buprenorphine
AU2022270208A1 (en) * 2021-05-05 2023-12-07 Lyndra Therapeutics, Inc. Gastric residence systems comprising methadone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382577C (en) 1999-08-27 2008-01-22 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
EP1554290B1 (en) 2002-10-25 2009-09-30 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法,以及长效作用镇痛药学组合物
TWI226830B (en) * 2002-11-12 2005-01-21 Chi Mei Foundation Medical Ct Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgesic pharmaceutical compositions
ATE382050T1 (de) * 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
WO2007061739A2 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
GB0606124D0 (en) 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
ES2549115T3 (es) * 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations

Also Published As

Publication number Publication date
JP6929367B2 (ja) 2021-09-01
MX2019002675A (es) 2019-08-01
DK3512518T3 (da) 2023-01-30
AU2017325910B2 (en) 2020-08-27
ZA201900890B (en) 2021-08-25
CA3033046C (en) 2021-09-07
KR20190052021A (ko) 2019-05-15
PT3512518T (pt) 2023-01-27
US20190142823A1 (en) 2019-05-16
EP3512518A1 (en) 2019-07-24
EP3512518A4 (en) 2020-06-03
KR102244500B1 (ko) 2021-04-26
MY196269A (en) 2023-03-24
CN109789137B (zh) 2023-01-13
JP2019529543A (ja) 2019-10-17
RS63894B1 (sr) 2023-02-28
EP3512518B1 (en) 2022-10-26
PE20190707A1 (es) 2019-05-17
SMT202300006T1 (it) 2023-03-17
CL2019000624A1 (es) 2019-06-14
CA3033046A1 (en) 2018-03-22
SI3512518T1 (sl) 2023-04-28
NZ750367A (en) 2021-01-29
FI3512518T3 (fi) 2023-01-31
TWI743193B (zh) 2021-10-21
AU2017325910A1 (en) 2019-02-21
US10744132B2 (en) 2020-08-18
ES2934721T3 (es) 2023-02-24
CN109789137A (zh) 2019-05-21
PH12019500466A1 (en) 2020-01-20
HRP20230062T1 (hr) 2023-03-31
RU2019102895A3 (enExample) 2020-12-01
MX374304B (es) 2025-03-06
RU2747306C2 (ru) 2021-05-04
CO2019003632A2 (es) 2019-06-28
LT3512518T (lt) 2023-02-10
WO2018050043A1 (en) 2018-03-22
RU2019102895A (ru) 2020-08-03
BR112019004923A2 (pt) 2019-06-04
TW201821077A (zh) 2018-06-16
PL3512518T3 (pl) 2023-03-27
AR110468A1 (es) 2019-04-03
HUE060906T2 (hu) 2023-04-28
SG11201901294QA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
NL301360I2 (nl) talquetamab
DK3405050T3 (da) Børnesikret snusbeholder
EP3338458A4 (en) EARPHONES
DK3510279T3 (da) Hvirvelafløsningsindretning
CL2016002143S1 (es) Inodoro
EP3450133A4 (en) Liquid blow molding method
DK3094200T3 (da) Kæbebeskyttelse
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
DK3445708T3 (da) Stigbøjle
EP3364945C0 (en) SOLID FORMULATION
EP3560512A4 (en) COMPOSITION OF VACCINE AGAINST ZONA
FI20145422A7 (fi) Asuste
DK3452590T3 (da) Plademagnet
EP3960158C0 (en) AMLODIPINE FORMULATIONS
ES1106784Y (es) Secamanos
FI3512518T3 (fi) Hitaasti vapautuvia buprenorfiiniformulaatioita
EP3444345C0 (en) MICRO-143 RNA DERIVATIVE
EP3426849C0 (en) SOIL PROTECTION
DE112017000734A5 (de) Glycolsensor
DE112017006386A5 (de) Schraubarbeitszylinder
DK3323708T3 (da) Bovfender
DK3430609T3 (da) Smartflag
DK3295800T3 (da) Sandwichkiksindretning
BR112018000396A2 (pt) composições de nicergolina de liberação modificada